Study to Assess the Safety and Efficacy of the IUB SEAD Device

  • STATUS
    Recruiting
  • participants needed
    30
  • sponsor
    Ocon Medical Ltd.
Send
Updated on 16 February 2024
See if I qualify

Summary

Pre-pivotal, randomized study to assess the safety and efficacy of the IUB SEAD device in women suffering from abnormal uterine bleeding.

Description

Chronic abnormal uterine bleeding (AUB), involving menstrual bleeding of abnormal quantity, duration, or schedule, is experienced by 10-35% of women, and can markedly impact everyday activities, can lead to iron deficiency and in severe cases, can necessitate emergency medical care.

While pharmacologic treatment options exist, some women desire a treatment that requires less maintenance or is definitive. Endometrial ablation is a minimally invasive approach applied to manage AUB and can be performed using resectoscopic instruments or with a non-resectoscopic approach, in which the device is inserted into the uterine cavity and delivers energy to uniformly destroy the uterine lining. Non-resectoscopic endometrial ablation has become an accepted office-based procedure, but requires training in administration and response to complications of conscious sedation and of assisting personnel.

The IUB SEAD device is a novel Spherical Endometrial Ablation Device, developed to allow for a simple, office-based chemical endometrial ablation to treat AUB. The suggested procedure is expected to be simpler than the currently available ablation methods and to result in a clinically meaningful delay or abolishment of the need for hysterectomy

Details
Condition Abnormal Uterine Bleeding
Age 35years - 50years
Treatment SEAD treatment
Clinical Study IdentifierNCT04381416
SponsorOcon Medical Ltd.
Last Modified on16 February 2024

Eligibility

 Yes No Not Sure

Inclusion Criteria

Female subject age 35 to 50 years, inclusive
Suffering from heavy menstrual bleeding with no definable organic cause and are candidates for global endometrial ablation or surgical treatment
Have a histological finding in a recent (max 4-month-old, with a window of 1 month) endometrial biopsy (Pipelle or other non-treatment-based biopsy) that demonstrates benign endometrial histology: proliferative endometrium and/or disordered endometrium and/or histological findings associated with dysfunctional endometrium (e.g. irregular shading, un-ovulatory bleeding and such); no histological findings of hyperplasia are allowed
Premenopausal status confirmed by FSH level measurement at screening (FSH < 40 IU/L). FSH level measurement will be repeated in case of a borderline result
Screening hemoglobin levels >9.0 g/dL
Uterine sound measurement of 6.5-11 cm (external os to internal fundus)
PBAC score of >150 for 3 months prior to study treatment or PBAC score >150 one month prior to study treatment for women who had at least 3 prior months (documented) of failed medical therapy
Predictable, cyclic menstrual cycles
Negative serum pregnancy test at the Screening visit and on the day of SEAD treatment
Sexually active women must agree to use an effective method of contraception throughout the course of the study. For this study, effective methods of contraception are considered to be those listed below
Barrier method, i.e., (a) condom (male or female) with spermicide or (b) diaphragm with spermicide or
Vasectomy (partner), or
Abstinence, if in line with the preferred and usual lifestyle of the subject [where abstinence is defined as refraining from heterosexual intercourse]
Subject able to understand and sign a written informed consent form
Subject willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures
Demonstrates an understanding of how to record menstrual blood loss using a menstrual pictogram

Exclusion Criteria

Pregnant women or those who desire to conceive at any time in the future
Congenital malformation of the uterine cavity (bicornuate, septate)
Inability to visualize the uterine cavity because of intracavitary pathology and/or significant uterine asymmetry, including patients with submucous myomas and/or polyps and synechiae that heavily distort the uterine cavity
Underwent prior uterine surgery that interrupts the integrity of the uterine wall (e.g., transmural myomectomy, classical Cesarean section, endometrial ablation, hysteroscopic resection) or a uterine biopsy accompanied by curettage in the last 12 months
Have abnormal endometrial biopsy (i.e., unresolved adenomatous complex hyperplasia, endometrial cancer)
Have a documented clinical history of metal allergy or hypersensitivity
Suffers from active endometritis, active pelvic inflammatory disease (PID) or active sexually transmitted disease (STD)
Suffers from active infection of the genitals, vagina, cervix, or uterus
Presence of bacteremia, sepsis, or other active systemic infection
Known/suspected abdominal, pelvic, or gynecological malignancy within the past 5 years
Known clotting defects or bleeding disorders or subjects who went through blood transfusion (for any reason) in the three months prior enrollment
Currently using anticoagulant treatment
Subjects with abnormal Papanicolaou (Pap) test or atypical squamous cells of undetermined significance (ASCUS) with positive high-risk human papilloma virus (HPV) test result within the appropriate screen timeframe, and prior to SEAD treatment. Alternatively, a colposcopy performed prior to SEAD treatment, that showed evidence of dysplasia requiring treatment. In case treatment was performed > 6 months prior to enrollment and follow-up was done with no evidence of disease by clinical evaluation, the subject is eligible
Previously had endometrial ablation procedure of any kind
Suffers from clinically significant adenomyosis indicated by subject complaints, imaging or clinician's judgment
Presence of an implantable contraceptive device
Post-partum 6-months
Currently participating in or considering participation in a research study of an investigational drug or device that would begin during the course of this investigational study
Any general health or mental, or other situation or condition which, in the opinion of the Investigator, could present an increased risk for the subject or impact the subject's ability to comply with protocol requirements
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Other language

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.